Premium
Deferoxamine treatment during pregnancy: Is it harmful?
Author(s) -
Singer Sylvia Titi,
Vichinsky Elliott P.
Publication year - 1999
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(199901)60:1<24::aid-ajh5>3.0.co;2-c
Subject(s) - deferoxamine , medicine , pregnancy , thalassemia , chelation therapy , gestation , beta thalassemia , obstetrics , pediatrics , genetics , biology
The use of the iron chelator, Deferoxamine (DFO), in pregnant thalassemia women with iron overload has been generally avoided due to fear of its potential teratogenicity. We describe a case of a pregnant thalassemia major patient with iron overload, who received DFO throughout her second and third trimesters and gave birth to a healthy infant, who had no findings of DFO toxicity at birth and at a later follow‐up. Review of the literature discloses over 40 other cases in which DFO was given in various periods of gestation without evidence of teratogenic effect. Sufficient documentation exists, therefore, to suggest that DFO can be considered for use in cases of pregnant women who need iron chelation treatment. Am. J. Hematol. 60:24–26, 1999. © 1999 Wiley‐Liss, Inc.